Issue link: http://www.e-digitaleditions.com/i/552614
References 1. Fink JB, Rubin BK. Problems with inhaler use: A call for improved clinician and patient education. Respir. Care. 2005;50(10):1360-1374. 2. Ruscin JM, Semla TP. Assessment of medication management skills in older outpatients. Ann. Pharmacother. 1996;30:1083-1088. 3. Nikolaus T, Kruse W, Bach M, Specht-Leible N, Oster P, Schlierf G. Elderly patients' problems with medication. An in-hospital and follow-up study. Eur. J. Clin. Pharmacol. 1996;49(4):255-259. 4. Laube BL, Janssens HM, de Jongh FHC, Devadason SG, Dhand R, Diot P, Everard ML, Horvath I, Navalesi P, Voshaar T, Chrystyn H. What the pul- monary specialist should know about the new inhalation therapies. Eur. Respir. J. 2011;37:1308-1331. 5. Ortman JM, Velkoff VA, Hogan H. An Aging Nation: The older population in the United States: Population estimates and projections. United States Census Bureau. US Department of Commerce. May 2014. Available at: http://www.census.gov/prod/2014pubs/p25-1140.pdf; accessed June 13, 2015. 6. Rutherford T. Population aging: Statistics. Standard Note SN/SG/3228. UK House of Commons Library, Westminster, London, UK. February 2012. Avail- able at: www.parliament.uk/briefing-papers/sn03228.pdf; accessed June 25, 2015. 7. Weers JG, Ung K, Chan L, Glusker M, Ament B, Le J, Rao N, Axford G, Maltz DS. Minimizing human factor effects through improved inhaler design. Respira- tory Drug Delivery 2012. Volume 1, 2012:217-226. 8. Leiner S, Parkins D, Lastow O. Inhalation devices and patient interface: Human factors. AAPSJ. 2015;17(2):457-461. 9. Lavorini F, Magnan A, Dubus JC, Voshaar T, Corbetta L, Broeders M, Dekhuijzen R, Sanchis J, Viejo JL, Barnes P, Corrigan C, Levy M, Crompton GK. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir. Med. 2008;102(4):593-604. 10. Al-Showair RA, Tarsin WY, Assi KH, Pearson SB, Chrystyn H. Can all patients with COPD use the correct inhalation flow with all inhalers and does training help? Respir. Med. 2007;101(11):2395–2424. 11. Chatila WM, Thomashow BM, Minai OA, Criner GJ, Make BJ. Comorbidi- ties in chronic obstructive pulmonary disease. Proc. Am. Thoracic Soc. 2008;5:549-555. 12. Global Initiative for Asthma (GINA) and Global Initiative for Chronic Obstructive Pulmonary Disease (COPD). Diagnosis of diseases of chronic air- flow limitation: Asthma, COPD and asthma-COPD overlap syndrome (ACOS). 2015. Available at: http://www.ginasthma.org/local/uploads/files/ACOS_2015. pdf; accessed May 4, 2015. 13. Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2015. Available at: http://www.ginasthma.org/; accessed May 4, 2015. 14. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2015. Available at: http://www.goldcopd.org/; accessed May 4, 2015. 15. Radder JE, Shapiro SD, Berndt A. Personalized medicine for chronic, com- plex diseases: Chronic obstructive pulmonary disease as an example. Personalized Med. 2014;11(7):669-679. 16. Suizza S, Barnes PJ. Inhaled corticosteroids in COPD: The case against. Eur. Respir. J. 2009;34:13-16. 17. Murphy KR, Bender BG. Treatment of moderate to severe asthma: Patient perspectives on combination inhaler therapy and implications for adherence. J. Asthma Allergy. 2009;2:63-72. 18. Ari A. Jet, Ultrasonic, and mesh nebulizers: An evaluation of nebulizers for better clinical outcomes. Eurasian J. Pulmonol. 2014;16:1-7. 19. Cipolla D, Chan HK, Schuster J, Farina D. Personalized medicine: Develop- ment of inhalation systems tailored to the individual. Ther. Deliv.2010;1(5): 667-682. 20. Corr D, Dolovich M, McCormack D, Ruffin R, Obminski G, Newhouse M. Design and characteristics of a portable breath actuated, particle size selective medical aerosol inhaler. J. Aerosol Sci. 1982;13:1–7. 21. Lavorini F. The Challenge of Delivering Therapeutic Aerosols to Asthma Patients. ISRN Allergy, 2013; Article ID 102418; Available at: http://www.hin dawi.com/journals/isrn/2013/102418/; accessed May 3, 2015. 22. Dalby R, Spallek M, Voshaar T. A review of the development of Respimat® soft mist inhaler. Int. J. Pharm. 2004;283(1-2):1-9. 23. Hess DR. Nebulizers: Principles and performance. Respir. Care. 2000;45(6):609-622. 24. Van der Palen J, Klein JJ, van Herwaarden CLA, Zielhuis GA, Seydel ER. Multiple inhalers confuse asthma patients. Eur Respir J. 1999;14:1034-1037. 25. Vincken W, Dekhuijzen R, Barnes P. The ADMIT series – Issues in Inhala- tion Therapy: How to choose inhaler devices for the treatment of COPD. Prim. Care Respir. J. 2010;19(1):10-20. 26. Mitchell JP, Coppolo DP, Nagel MW. Electrostatics and inhaled medica- tions: Influence on delivery via pressurized metered-dose inhalers and add-on devices. Respir. Care. 2007;52(3):283-300. 27. Mitchell JP. Addressing the patient-device use interface: Why patient- friendly features are important. Inhalation. 2012;6(4):21-26. 28. Mitchell JP, Nagel MW, Bates SL, Doyle CC. An in vitro study to investigate the use of a breath-actuated, small-volume, pneumatic nebulizer for the delivery of methacholine chloride bronchoprovocation agent. Respir Care. 2003;48(1):46-51. 29. International Standards Organization (ISO). Aerosol drug delivery device design verification: Requirements and test methods. ISO 20072:2009, Geneva, Switzerland. 30. US Food and Drug Administration. Draft Guidance for Industry and Food and Drug Administration Staff: Applying Human Factors and Usability Engi- neering to Optimize Medical Device Design. Silver Spring, MD, USA, June 22, 2011. Available at: http://www.fda.gov/RegulatoryInformation/Guidances/ ucm259748.htm; accessed May 14, 2015. 31. UK Medicines and Healthcare Regulatory Agency (MHRA). Best practice guidance on patient information leaflets. Guidance 0712. London, UK, July 2012. 32. Adepu R, Swamy MK. Development and evaluation of patient information leaflets (PIL) usefulness. Indian J. Pharm. Sci. 2012;74(2):174-178. 33. Van der Palen J, Klein JJ, Kerkhoff AH, van Herwaarden CL, Seydel ER. Evaluation of the long-term effectiveness of three instruction modes for inhaling medicines. Patient Educ. Couns. 1997;32(1 Suppl):S87–S95. 34. Crompton GK, Barnes PJ, Broeders M, Corrigan C, Corbetta L, Dekhuijzen R, Dubus JC, Magnan A, Massone F, Sanchis J, Viejo JL, Voshaar T. The need to improve inhalation technique in Europe: A report by the Aerosol Drug Manage- ment Improvement Team. Respir. Med. 2006; 100: 1479–1494. 35. Hesselink AE, Penninx BW, van der Windt DA, van Duin BJ, de Vries P, Twisk JW, Bouter LM, van Eijk JT. Effectiveness of an education programme by a general practice assistant for asthma and COPD patients: Results from a ran- domised controlled trial. Patient Educ. Couns. 2004;55(1):121–128. Jolyon Mitchell, PhD, FRSC(UK), CChem, CSci is an Affiliate Pro- fessor at the Daniel K. Inouye College of Pharmacy, University of Hawaii and an Adjunct Professor at the University of Western Ontario and owns Jolyon Mitchell Inhaler Consulting Services, Inc.,1154 St. Anthony Road, London, Ontario, N6H 2R1, Canada, Tel: +1 519 472-5364, mitchelljolyon@gmail.com. 20 AUGUST 2015 Inhalation